AU2005202416B2 - Regulation of phospholipase D activity - Google Patents
Regulation of phospholipase D activity Download PDFInfo
- Publication number
- AU2005202416B2 AU2005202416B2 AU2005202416A AU2005202416A AU2005202416B2 AU 2005202416 B2 AU2005202416 B2 AU 2005202416B2 AU 2005202416 A AU2005202416 A AU 2005202416A AU 2005202416 A AU2005202416 A AU 2005202416A AU 2005202416 B2 AU2005202416 B2 AU 2005202416B2
- Authority
- AU
- Australia
- Prior art keywords
- pld
- psdp
- lipoxin
- pmn
- lxa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000553 Phospholipase D Proteins 0.000 title claims description 123
- 102000011420 Phospholipase D Human genes 0.000 title claims description 121
- 230000000694 effects Effects 0.000 title description 64
- 230000033228 biological regulation Effects 0.000 title description 17
- 229930184725 Lipoxin Natural products 0.000 claims description 64
- 150000002639 lipoxins Chemical class 0.000 claims description 60
- 238000000034 method Methods 0.000 claims description 45
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 30
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 15
- 206010061218 Inflammation Diseases 0.000 claims description 12
- 230000004054 inflammatory process Effects 0.000 claims description 12
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 10
- 238000001727 in vivo Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- ATZKAUGGNMSCCY-VYCBRMPGSA-N presqualene diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\[C@H]1[C@H](COP(O)(=O)OP(O)(O)=O)[C@@]1(C)CC\C=C(/C)CCC=C(C)C ATZKAUGGNMSCCY-VYCBRMPGSA-N 0.000 description 86
- 150000001875 compounds Chemical class 0.000 description 65
- 125000004432 carbon atom Chemical group C* 0.000 description 60
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 53
- 150000002632 lipids Chemical class 0.000 description 35
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 31
- 229960001138 acetylsalicylic acid Drugs 0.000 description 31
- 125000000217 alkyl group Chemical group 0.000 description 30
- 239000000203 mixture Substances 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 28
- 230000004913 activation Effects 0.000 description 26
- 102000005962 receptors Human genes 0.000 description 25
- 108020003175 receptors Proteins 0.000 description 25
- 238000007634 remodeling Methods 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 22
- 210000000440 neutrophil Anatomy 0.000 description 21
- 102000004190 Enzymes Human genes 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 17
- -1 Thromboxane Leukotriene Chemical class 0.000 description 17
- 229940088598 enzyme Drugs 0.000 description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 17
- 229910019142 PO4 Inorganic materials 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- 235000021317 phosphate Nutrition 0.000 description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- 230000004044 response Effects 0.000 description 15
- 230000011664 signaling Effects 0.000 description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 229910052736 halogen Inorganic materials 0.000 description 14
- 150000002367 halogens Chemical class 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 102000003680 Leukotriene B4 receptors Human genes 0.000 description 13
- 108090000093 Leukotriene B4 receptors Proteins 0.000 description 13
- 125000004093 cyano group Chemical group *C#N 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 230000003834 intracellular effect Effects 0.000 description 12
- 230000003389 potentiating effect Effects 0.000 description 12
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 230000019491 signal transduction Effects 0.000 description 11
- 230000004068 intracellular signaling Effects 0.000 description 10
- GPKFJNOMPPCLGX-VYCBRMPGSA-N presqualene monophosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\[C@H]1[C@H](COP(O)(O)=O)[C@@]1(C)CC\C=C(/C)CCC=C(C)C GPKFJNOMPPCLGX-VYCBRMPGSA-N 0.000 description 10
- IXAQOQZEOGMIQS-JEWNPAEBSA-N 15-epi-lipoxin A4 Chemical compound CCCCC[C@@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCCC(O)=O IXAQOQZEOGMIQS-JEWNPAEBSA-N 0.000 description 9
- VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 description 9
- VWFJDQUYCIWHTN-FBXUGWQNSA-N Farnesyl diphosphate Natural products CC(C)=CCC\C(C)=C/CC\C(C)=C/COP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-FBXUGWQNSA-N 0.000 description 9
- 102100021126 N-formyl peptide receptor 2 Human genes 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 9
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 9
- 230000009466 transformation Effects 0.000 description 9
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 8
- 101000818546 Homo sapiens N-formyl peptide receptor 2 Proteins 0.000 description 8
- 101000931587 Mus musculus Formyl peptide receptor-related sequence 1 Proteins 0.000 description 8
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 230000036755 cellular response Effects 0.000 description 8
- 125000000753 cycloalkyl group Chemical group 0.000 description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 229940031439 squalene Drugs 0.000 description 8
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000010452 phosphate Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 230000001960 triggered effect Effects 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 6
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000005754 cellular signaling Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- IXAQOQZEOGMIQS-SSQFXEBMSA-N lipoxin A4 Chemical compound CCCCC[C@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCCC(O)=O IXAQOQZEOGMIQS-SSQFXEBMSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 150000003180 prostaglandins Chemical class 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
- IXAQOQZEOGMIQS-ORRYEOPJSA-N Lipoxin A Natural products CCCCCC(O)C=CC=C/C=C/C=C/C(O)C(O)CCCC(=O)O IXAQOQZEOGMIQS-ORRYEOPJSA-N 0.000 description 5
- 102000015439 Phospholipases Human genes 0.000 description 5
- 108010064785 Phospholipases Proteins 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 125000003710 aryl alkyl group Chemical group 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- UXVRTOKOJOMENI-ICTGYCPSSA-N (6e,8e,10e,12e)-5,14,15-trihydroxyicosa-6,8,10,12-tetraenoic acid Chemical compound CCCCCC(O)C(O)\C=C\C=C\C=C\C=C\C(O)CCCC(O)=O UXVRTOKOJOMENI-ICTGYCPSSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 102000016954 ADP-Ribosylation Factors Human genes 0.000 description 4
- 108010053971 ADP-Ribosylation Factors Proteins 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- 102000005720 Glutathione transferase Human genes 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000001851 biosynthetic effect Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000035605 chemotaxis Effects 0.000 description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 4
- 229960001231 choline Drugs 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000006072 paste Substances 0.000 description 4
- 150000008103 phosphatidic acids Chemical class 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000018 receptor agonist Substances 0.000 description 4
- 229940044601 receptor agonist Drugs 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 235000010487 tragacanth Nutrition 0.000 description 4
- 239000000196 tragacanth Substances 0.000 description 4
- 229940116362 tragacanth Drugs 0.000 description 4
- 230000008728 vascular permeability Effects 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 240000007124 Brassica oleracea Species 0.000 description 3
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 3
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 3
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 3
- 101710091342 Chemotactic peptide Proteins 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 3
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 3
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 3
- 102000004722 NADPH Oxidases Human genes 0.000 description 3
- 108010002998 NADPH Oxidases Proteins 0.000 description 3
- 102100032967 Phospholipase D1 Human genes 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 208000038016 acute inflammation Diseases 0.000 description 3
- 230000006022 acute inflammation Effects 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 150000001982 diacylglycerols Chemical class 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 150000002066 eicosanoids Chemical class 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000000224 granular leucocyte Anatomy 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000008611 intercellular interaction Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 102000006240 membrane receptors Human genes 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- 230000006441 vascular event Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 241000721179 Clarias Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101001074954 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 5-phosphatase A Proteins 0.000 description 2
- 101000730670 Homo sapiens Phospholipase D2 Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 101000761444 Loxosceles laeta Dermonecrotic toxin Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102100035985 Phosphatidylinositol 4,5-bisphosphate 5-phosphatase A Human genes 0.000 description 2
- 102100032983 Phospholipase D2 Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 102000014384 Type C Phospholipases Human genes 0.000 description 2
- 108010079194 Type C Phospholipases Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002975 chemoattractant Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 108010002267 phospholipase D2 Proteins 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 150000003505 terpenes Chemical group 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- MMWCIQZXVOZEGG-UHFFFAOYSA-N 1,4,5-IP3 Natural products OC1C(O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(O)C1OP(O)(O)=O MMWCIQZXVOZEGG-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010022535 Farnesyl-Diphosphate Farnesyltransferase Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101001040875 Homo sapiens Glucosidase 2 subunit beta Proteins 0.000 description 1
- 101000730665 Homo sapiens Phospholipase D1 Proteins 0.000 description 1
- 101000818522 Homo sapiens fMet-Leu-Phe receptor Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108010014691 Lithostathine Proteins 0.000 description 1
- 102100027361 Lithostathine-1-alpha Human genes 0.000 description 1
- 101000964266 Loxosceles laeta Dermonecrotic toxin Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 101710091942 N-formyl peptide receptor 2 Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 101150020891 PRKCA gene Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 101150111584 RHOA gene Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 102100037997 Squalene synthase Human genes 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- VNWKTOKETHGBQD-AKLPVKDBSA-N carbane Chemical class [15CH4] VNWKTOKETHGBQD-AKLPVKDBSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000006690 co-activation Effects 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007247 enzymatic mechanism Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 102100021145 fMet-Leu-Phe receptor Human genes 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- UXVRTOKOJOMENI-WLPVFMORSA-N lipoxin B4 Chemical compound CCCCC[C@H](O)[C@H](O)\C=C\C=C\C=C/C=C/[C@@H](O)CCCC(O)=O UXVRTOKOJOMENI-WLPVFMORSA-N 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
P001 Section 29 Regulation 3.2(2)
AUSTRALIA
Patents Act 1990 COMPLETE SPECIFICATION STANDARD PATENT Application Number: Lodged: Invention Title: Regulation of phospholipase D activity The following statement is a full description of this invention, including the best method of performing it known to us: REGULATION OF PHOSPHOLIPASE D ACTIVITY BACKGROUND OF THE INVENTION Neutrophil (PMN) activation plays a central role in diverse host responses, such as host defense, inflammation and reperfusion injury (Weissmann, Smolen, J. and Korchak, H. M. (1980) Release of inflammatory mediators from stimulated neutrophils.
N. Engl. J Med. 303, 27-34). In response to inflammatory stimuli, PMN phospholipases are activated to remodel cell membranes and generate bioactive lipids that serve as intraor extracellular mediators in the transduction of functional responses (Serhan, C. N., Haeggstrom, J. and Leslie, C. C. (1996) Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 10, 1147-1158). Important components of microbicidal and acute inflammatory responses include reactive oxygen species and granule enzymes that are targeted to phagocytic vacuoles, but aberrant release of these potentially toxic agents can lead to amplification of inflammation as well as tissue injury and are implicated in a wide range of diseases (Weiss, S. J. (1989) Tissue destruction by neutrophils. N. Engl. J. Med. 320, 365-376). To prevent an over-exuberant inflammatory response and limit damage to the host, these PMN programs are tightly regulated. The host mediators serving as endogenous anti-inflammatory or protective signals are only recently being appreciated (Serhan, C. N. (1994) Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim. Biophys. Acta 1212, 1-25).
SUMMARY OF THE INVENTION The present invention pertains to methods for modulating a disease or condition associated with phospholipase D (PLD) activity. The methods include administration to a subject, an effective anti-PLD amount of a lipoxin analog having the formula described infra, such that the PLD initiated activity is modulated.
The present invention also pertains to methods for treating phosphlipase D (PLD) activity in a subject. The methods include administration of an effective anti- PLD amount of a lipoxin analog described infra, such that PLD initiated activity is treated.
The present invention further pertains to methods for modulating a disease or condition associated with phospholipase D (PLD) initiated generation of superoxide or degranulation activity in a subject. The methods include, administration of an effective anti-PLD amount of a lipoxin analog described infra, such that a disease or condition associated with initiated by PLD generation of superoxide or degranulation activity, is modulated.
The present invention further relates to methods for treating phospholipase
D
(PLD) initiated superoxide generation or degranulation activity in a subject. The methods include administration of an effective anti-PLD amount of a lipoxin analog described infra, such that PLD initiated superoxide generation or degranulation activity is treated.
In preferred embodiments, the methods of the invention are performed in vitro or in vivo.
BRIEF DESCRIPTION OF THE DRAWINGS The invention will be more fully understood from the following detailed description taken in conjunction with the accompanying drawings, in which: Figure 1 shows that LTB 4 rapidly remodels PSDP in human PMN: biosynthetic switch by an aspirin-triggered LXA, analog. Panel A: Scheme for aspirin-triggered epi-LXA biosynthesis and structure of the stable analog, 15-epi-1 6 -para-fluoro-phenoxy-
LXA
4 -methyl ester (15-epi-LXa) (left), and hypothetical scheme for PIPP signaling (right). PMN were labeled with [y- 32 P]-ATP and incubated (12.5 x 106ml-', 37 0 C) with
LTB
4 100 nM), 15-epi-LXa 100 nM), vehicle 0.1% ethanol) or (100 nM, 5 min) followed by LTB 4 100 nM). Non-saponifiable lipids were extracted and separated by TLC, and 3 P]-incorporation was quantitated by phosphoimaging (see Methods). Values are densitometric measurements. Panel B reports a representative time course and Panel C shows the change (mean at 60 seconds. *P 0.05 by Student's t-test.
Figure 2 demonstrates 15-epi-LXA, analog inhibits LTB 4 -stimulated PLD activity and superoxide anion generation. Cell lysates (2-5 x 106 cells, 90-130 gg protein) were prepared from the same aliquots of PMN used to determine PSDP (see Fig. 1 Methods), warmed to 37 0 C and exposed to PC (2 mM in 50 mM Tris-HCl, pH 7.5, plus mM CaCl 2 Reactions were terminated at 30 sec intervals and choline release was quantitated Values in Panel A are representative d=4) of the impact of LXa on choline release, and Panel B shows the change at 60 seconds (mean Superoxide anion generation by freshly isolated human PMN was determined (10 min, 37 0 C) for LTB 4 (100 nM), 15-epi-LXa (100 nM), and increasing concentrations of LXa (1-100 nM, 5 min, 37 0 C) followed by LTB4 (100 nM, 10 min, 37°C). Values reported in Panel C are the mean S.E. for n=3 separate PMN donors. *P 0.05 by Student's t-test.
Figure 3 demonstrates PSDP inhibits phospholipase D. Purified PLD (3 units EC 3.1.4.4./125 Vl) was warmed (3 min, 300C) and exposed to PSDP (10-1000 nM, 5 min, 0 C) or vehicle (0.04% ethanol final cone.) followed by PC (0.5-5 mM) in 50 mM Tris- HCL pH 7.5) plus 30 mM CaCI 2 Reactions were terminated at 30 sec intervals and choline release quantitated as in Fig. 2 legend. Values represent the mean for n>4 for reactions in the absence of PSDP r 2 0.963) and the mean for n>3 with PSDP r' 0.995, 0.971 and 0.953 for 10, 100 and 1000 nM, respectively). CS Chem3D Pro software (CambridgeSoft Corp., Cambridge, MA) was used to calculate an energy minimized model of PSDP (inset).
DETAILED DESCRIPTION OF THE INVENTION The features and other details of the invention will now be more particularly described and pointed out in the claims. It will be understood that the particular embodiments of the invention are shown by way of illustration and not as limitations of the invention. The principle features of this invention can be employed in various embodiments without departing from the scope of the invention.
It is of wide interest to understand how opposing extracellular signals (positive or negative) are translated into intracellular signaling events. Receptor-ligand interactions initiate the generation ofbioactive lipids by human neutrophils (PMN) that serve as signals to orchestrate cellular responses important in host defense and inflammation. A novel polyisoprenyl phosphate (PIPP) signaling pathway was identified and it was found that one of its components, presqualene diphosphate (PSDP), is a potent negative intracellular signal in PMN that regulates superoxide anion generation by several stimuli including phosphatidic acid (Levy et al. (1998) Nature. 389, 985-990). It was determined intracellular PIPP signaling by autacoids with opposing actions on PMN leukotriene B 4 (LTB), a potent chemoattractant, and lipoxin A 4 (LXA4), a "stop signal" for recruitment.
LTB
4 receptor activation initiated a rapid decrease in PSDP levels concurrent with activation of PLD and cellular responses. In sharp contrast, activation of the LXA 4 receptor reversed LTB 4 -initiated PSDP remodeling leading to an accumulation of PSDP and potent inhibition of both PLD and superoxide anion generation. Thus, an inverse relationship was established for PSDP levels and PLD activity with two PMN ligands that evoke opposing responses. In addition, PSDP directly inhibited both isolated human recombinant (Ki 6 nM) and plant (Ki 20 nM) PLD. Together, these findings link PIPP remodeling to intracellular regulation of PMN function and suggest a role for PIPPs as lipid repressors in signal transduction, a novel mechanism that may also explain aspirin's suppressive actions in vivo in cell signaling.
Bioactive lipids are rapidly generated by activation of cell surface receptors that carry either specific positive or negative signals to modulate cellular responses. This is exemplified by the related eicosanoids, leukotriene B 4
(LTB
4 a potent chemoattractant (Borgeat, and Naccache, P. H. (1990) Biosynthesis and biological activity of leukotriene B 4 Clin Biochem. 23, 459-468), and lipoxin A 4
(LXA
4 an endogenous "stop signal" for PMN recruitment (Serhan, C. N. (1994) Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim. Biophys. Acta 1212, 1-25). LTB 4 and LXA 4 interact with highly specific and distinct G protein-coupled membrane receptors (Yokomizo, Izumi, Chang, Takuwa, and Shimizu, T. (1997) A G-proteincoupled receptor for leukotriene B 4 that mediates chemotaxis. Nature 387, 620-624; Fiore, Romano, Reardon, E. and Serhan, C. N. (1993) Induction of functional lipoxin A 4 receptors in HL-60 cells. Blood 81, 3395-3403). They each evoke opposing PMN responses, including LXA 4 inhibition of LTB 4 -initiated chemotaxis, adhesion and transmigration (Serhan, C. N. (1994) Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim. Biophys. Acta 1212, 1-25).
Abbreviations used throughout this application include: COX, cyclooxygenase; 15-epimer lipoxin; 15-epi-LXa, 15-epi-16-para-fluoro-phenoxy LXA 4 -methyl ester, FDP, farnesyl diphosphate; GST, glutathione-S-transferase; LTB 4 leukotriene B 4 LO, lipoxygenase; PA, phosphatidic acid; PC, phosphatidychloine; cPLD, cabbage phospholipase D; PIPP, polyisoprenyl phosphate; PMN, polymorphonuclear leukocytes; PSDP, presqualene diphosphate; PSMP, presqualene monophosphate; Sf9, Spodoptera frugiperda; TLC, thin-layer chromatography.
Aspirin is known to affect biosynthesis of lipid mediators and is widely used clinically for its anti-inflammatory properties. Mechanisms responsible for aspirin's antiinflammatory actions remain of considerable interest. In particular, new "super-aspirins" are sought that spare the gastrointestinal tract and do not possess the deleterious side effects of steroids (Isakson, Seibert, Masferrer, Salvemini, Lee, and Needleman, P. (1995) Discovery of a better aspirin. Advances in Prostaglandin, Thromboxane Leukotriene Research 23, 49-54). In one aspect it has been that, in addition to inhibiting prostanoid formation, aspirin triggers the endogenous generation of novel carbon 15 epimers of LX by transcellular routes (see Figure 1A) during inflammation in vivo between tissue resident cells and infiltrating leukocytes) (Chiang, Takano, Clish, C. Petasis, N. Tai, and Serhan, C. N. (1998) Aspirin-triggered 15-epi-lipoxin A 4 (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific 15-epi-LXA 4 ELISA. J. Pharmacol Exper.
Ther. 287, 779-790). These aspirin-triggered lipoxins (15-epi-LX) are even more potent than the native LX as inhibitors of PMN responses, in part because they are active longer (Serhan, C. Maddox, J. Petasis, N. Akritopoulou-Zanze, Papayianni, A., Brady, H. Colgan, S. and Madara, J. L. (1995) Design of lipoxin A 4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 34, 14609- 14615). PMN inhibition by LX and 15-epi-LX is evoked by specific receptor-activation of "inhibitory" signals and not via direct receptor level antagonism at LTB 4 receptors (Takano, Fiore, Maddox, J. Brady, H. Petasis, N. and Serhan, C. N.
(1997) Aspirin-triggered 15-epi-lipoxin A 4
(LXA
4 and LXA 4 Stable analogues are potent inhibitors of acute inflammation: Evidence for anti-inflammatory receptors. J. Exp. Med.
185, 1693-1704). Moreover, interest in the regulation of the LTB 4 receptor is heightened by the recent finding that LTB 4 receptors also serve as novel HIV-1 coreceptors (Owman, Garzino-Demo, Cocchi, Popovic, Sabirsh, and Gallo, R. (1998) The leukotriene B 4 receptor functions as a novel type of coreceptor mediating entry of primary HIV-1 isolates into CD4-positive cells. Proc. Natl. Acad Sci. 95, 9530-9534).
Despite -100 years of use, complete knowledge of aspirin's therapeutic impact is still evolving with many newly discovered clinical utilities (Marcus, A. J. (1995) Aspirin as prophylaxis against colorectal cancer. N. Engl. J. Med. 333, 656-658). Regular ingestion of aspirin decreases the incidence of myocardial infarction, colorectal carcinoma and Alzheimer's disease (Vainio, and Morgan, G. (1997) Aspirin for the second hundred years: new uses for an old drug. Pharmacol Toxicol 81, 151-152), but side effects from aspirin, such as gastrointestinal ulceration, can limit its use. The recent discovery of a second isoform of cyclooxygenase (COX) that is induced during inflammation has led to a search for "super-aspirins" that can selectively inhibit COX-2 without disrupting the protective constitutive functions of COX-1 (Isakson, Seibert, Masferrer, Salvemini, Lee, and Needleman, P. (1995) Discovery of a better aspirin. Advances in Prostaglandin, Thromboxane Leukotriene Research 23, 49-54; Herschman, H. R (1998) Recent progress in the cellular and molecular biology of prostaglandin synthesis. Trends in Cardiovasc. Med 8, 145-150). Of particular interest in this regard, 15-epi-LX, which inhibit PMN migration, are endogenous products of aspirin's acetylating ability that may underly some of the salutary benefits of aspirin.
Both LX and 15-epi-LX stable analogs were prepared, which like 15-epi-LXA 4 act via the LXA 4 receptor (Serhan, C. Maddox, J. Petasis, N. Akritopoulou-Zanze, I., Papayianni, Brady, H. Colgan, S. and Madara, J. L. (1995) Design of lipoxin
A
4 stable analogs that block transmigration and adhesion of human neutrophils.
Biochemistry 34, 14609-14615; Takano, Fiore, Maddox, J. Brady, H. R., Petasis, N. and Serhan, C. N. (1997) Aspirin-triggered 15-epi-lipoxin A 4
(LXA
4 and
LXA
4 Stable analogues are potent inhibitors of acute inflammation: Evidence for antiinflammatory receptors. J. Exp. Med 185, 1693-1704). Suitable methods of preparation of lipoxin compounds can also be found, for example, in U.S. Patent Nos. 5,411,951, 5,648,512, 5,650,435 and 5,750,354, incorporated herein by reference. For example, epi-16-para-fluoro-phenoxy-lipoxin
A
4 -methyl ester (15-epi-LXa) is a synthetic analog of 4 (Figure 1A, bottom left) that not only resists rapid inactivation but acts topically to inhibit PMN infiltration and vascular permeability in mouse ear skin inflammation (Takano, Clish, C. Gronert, Petasis, and Serhan, C. N. (1998) Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A 4 and novel lipoxin B 4 stable analogues. J. Clin.
Invest. 101, 819-826).
Elucidation of signaling pathway(s) responsible for receptor-operated blockage of PMN responses is of interest Signaling via phospholipase D (PLD) plays a pivotal role in mounting cellular responses. Within seconds of exposure to ligands, PLD hydrolyzes membrane phosphatidylcholine (PC) to generate phosphatidic acid (PA)(Billah, M. M., Eckel, Mullmann, T. Egan, R. and Siegel, M. I. (1989) Phosphatidylcholine hydrolysis by phospholipase D determines phosphatidate and diglyceride levels in chemotactic peptide-stimulated human neutrophils. Involvement of phsophatidate phosphohydrolase in signal transduction. J. Biol. Chem. 264, 17069-17077). Formation of PA temporally antecedes functional responses, including vesicle secretion and assembly of the NADPH oxidase (Wakelam, M. J. Martin, Hodgkin, M. N., Brown, Pettit, T. Cross, M. De Takats, P. and Reynolds, J. L. (1997) Role and regulation of phospholipase D activity in normal and cancer cells. Advances in Enzyme Regulation 37, 29-34; Olson, S. and Lambeth, J. D. (1996) Biochemistry and cell biology of phospholipase D in human neutrophils. Chem. Phys. Lipids 80, 3-19).
Several isozymes ofPLD1 and PLD2 were cloned and characterized (Steed, P. Clark, K. Boyar, W. and Lasala, D. J. (1998) Characterization of human PLD2 and the analysis of PLD isoform splice variants. FASEBJ. 12, 1309-1317), with PLDlb identified as a prominent isoform in human granulocytes (Martin, Saqib, K. Hodgkin, M.
Brown, F. Pettit, T. Armstrong, and Wakelam, M. J. 0. (1997) Role and regulation of phospholipase D signalling. Biochem. Soc. Trans. 25, 1157-1160). The complete DNA and amino acid sequences for human PLD is disclosed in Hammond et al. (1995) J. Biol. Chem. 270: 29640-29643, and Hammond et al. (1997) J. Biol.
Chem. 272: 3860-3868, the entire contents of which are incorporated herein by reference, and can also be found at GenBank Accession Nos. NM 002662 and U38545.
Recently, a novel polyisoprenyl phosphate (PIPP) signaling pathway was identified (Figure 1A) and found that, in PMN, presqualene diphosphate (PSDP) carries biological activity and serves as a negative intracellular signal that prevents superoxide anion generation by several stimuli including PA (Levy, B. Petasis, N. and Serhan, C. N. (1997) Polyisoprenyl phosphates in intracellular signalling. Nature 389, 985-989).
Because PLD activation is linked to superoxide anion generation (Agwu, D. McPhail, L. Sozzani, Bass, D. and McCall, C. E. (1991) Phosphatidic acid as a second messenger in human polymorphonuclear leukocytes. Effects on activation of NADPH oxidase. J. Clin. Invest. 88, 531-539), it was determined that PIPP signaling also modulates phospholipase activity critical to global cellular activation. It was found that that LTB 4 receptor activation rapidly degrades PSDP, a key component of PIPP signaling, that is reversed by a LXA 4 receptor agonist, (ii) that an aspirin-triggered 00 O LXA 4 stable analog potently inhibits LTB 4 -initiated PLD activation and superoxide c anion generation, and (iii) that PSDP directly inhibits both human recombinant O and plant PLD. These findings provide evidence for receptor-initiated PIPP Z remodeling as a regulatory signaling pathway.
00 oo c 5 The present invention pertains to methods for modulating a disease or condition associated with phospholipase D (PLD) activity. The methods include S administration to a subject, an effective anti-PLD amount of a lipoxin analog chaving the formula described infra, such that the PLD initiated activity is c- modulated.
0 10 The present invention also pertains to methods for treating phosphlipase D N (PLD) activity in a subject. The methods include administration of an effective anti-PLD amount of a lipoxin analog described infra, such that PLD initiated activity is treated.
The present invention further pertains to methods for modulating a disease or condition associated with phospholipase D (PLD) initiated generation of superoxide or degranulation activity in a subject. The methods include, administration of an effective anti-PLD amount of a lipoxin analog described infra, such that a disease or condition associated with initiated by PLD generation of superoxide or degranulation activity, is modulated.
The present invention further relates to methods for treating phospholipase D (PLD) initiated superoxide generation or degranulation activity in a subject.
The methods include administration of an effective anti-PLD amount of a lipoxin analog described infra, such that PLD initiated superoxide generation or degranulation activity is treated.
In preferred embodiments, the methods of the invention are performed in vitro or in vivo.
According to the present invention there is provided a method for treating phospholipase D (PLD) initiated polymorphoneutrophil (PMN) inflammation in a subject, comprising administering to the subject an effective anti-inflammatory amount of a lipoxin analog having the formula (I) wherein X is RI, OR 1 or SRi; wherein (i) (ii) (iii) (iv) (v) (vi)
R
1 is a hydrogen atom; an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched; a cycloalkyl of 3 to 10 carbon atoms; an aralkyl of 7 to 12 carbon atoms; phenyl; substituted phenyl wherein Zi, Zii, Ziii, Ziv, and Zv are each independently selected from -NO 2 -CN, 1
-SO
3 H, a hydrogen atom, halogen, methyl, -ORx, wherein Rx, is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl; (vii) a detectable label molecule; or (viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive; is SO 2 or provided when Q1 is CN, then X is absent; wherein Qi 00
O
CN wherein Q 3 and Q 4 are each independently O, S or NH; 0 Z wherein one of R 2 and R 3 is a hydrogen atom and the other is 00 5
H;
an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight Schain or branched; a cycloalkyl of 3 to 6 carbon atoms, inclusive; c an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight c- 10 chain or branched; or RaQ 2 Rb wherein Q 2 is or wherein Ra is alkylene of 0 to 6 0 carbons atoms, inclusive, which may be straight chain or branched and wherein Rb is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when Rb is 0, then Rb is a hydrogen atom; wherein R 4 is
H;
an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched; wherein R 5 is substituted phenyl Ziii Z, Zi, wherein Zi, Zi, Zii, Ziv, and Zv are each independently selected from -NO 2 -CN, 1
-SO
3 H, a hydrogen atom, halogen, methyl, -ORx, wherein Rx is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group; wherein Y 1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CHaZb where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen; wherein R 6 is a) H; b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched; wherein T is O or S, and pharmaceutically acceptable salts thereof.
In another embodiment, compounds useful in the invention have the formula (II) wherein X is R 1
OR
1 or SR 1 wherein R 1 is i) a hydrogen atom; ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched; iii) a cycloalkyl of 3 to 10 carbon atoms; iv) an aralkyl of 7 to 12 carbon atoms; v) phenyl; vi) substituted phenyl 00 00
O
C wherein Zi, Zij, Zi 1 Zi, and Z, are each independently selected from -NO 2 S-CN, 1
-SO
3 H, a hydrogen atom, halogen, methyl, wherein R is 1 5 hydroxyl; vii) a detectable label molecule; or viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive; wherein Q1 is SO 2 or provided when Q 1 is CN, then X is absent; wherein one of R 2 and R 3 is a hydrogen atom and the other is a) H; b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched; c) a cycloalkyl of 3 to 6 carbon atoms, inclusive; an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched; or RaQ2Rb wherein Q2 is or wherein Ra is alkylene of 0 to 6 carbon atoms, inclusive, which may be straight chain or branched and wherein Rb is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when Rb is 0, then Rb is a hydrogen atom; wherein R 4 is
H;
an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched; wherein Rs is substituted phenyl Zi t Z, Z Ziv wherein Zi, Zi, Zji, Ziv and Zv are each independently selected from -NO 2
-CN,
1
-SO
3 H, a hydrogen atom, halogen, methyl, -ORx, wherein Rx is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group; wherein Y 1 is -OH, methyl, -SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CH2Zb where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen; wherein R 6 is
H:
an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched; wherein T is O or S, and pharmaceutically acceptable salts thereof.
The invention is also directed to useful lipoxin compounds having the formula (III)
X
wherein X is R 1
OR
1 or SR 1 wherein R 1 is i) a hydrogen atom; ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched; iii) a cycloalkyl of 3 to 10 carbon atoms; iv) an aralkyl of 7 to 12 carbon atoms; v) phenyl; vi) substituted phenyl wherein Zi, Zi, Ziii, Ziv and Zv are each independently selected from -NO 2
-CN,
1
-SO
3 H, a hydrogen atom, halogen, methyl, -ORx, wherein Rx is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl; vii) a detectable label molecule; or viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive; 00 0 wherein Q 1 is SO 2 or provided when Q 1 is CN, then X is absent; O wherein one of R 2 and R 3 is a hydrogen atom and the other is Z a) H; 00 c-N 5 b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched; c) a cycloalkyl of 3 to 6 carbon atoms, inclusive; co d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be Nc straight chain or branched; or 0 10 e) RaQ2Rb wherein Q 2 is or wherein Ra is alkylene of 0 to 6 c-i carbons atoms, inclusive, which may be straight chain or branched and wherein Rb is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when Rb is 0, then Rb is a hydrogen atom; wherein R 4 is
H;
an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched; wherein R 5 is substituted phenyl zi
ZI
zZviv Z, Z,, wherein Zi, Zii, Ziii, Zi and Zv are each independently selected from -NO 2 -CN,
C(=O)-R
1
-SO
3 H, a hydrogen atom, halogen, methyl, -ORx, wherein Rx is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group; wherein R 6 is
H;
an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched; wherein T is O or S, and pharmaceutically acceptable salts thereof.
The invention is further directed to useful lipoxin compounds having the formula
(IV)
wherein X is R 1
OR
1 or SR 1 wherein R 1 is i) a hydrogen atom; ii) an alkyl of 1 to 8 carbon atoms, inclusive, which may be straight chain or branched; iii) a cycloalkyl of 3 to 10 carbon atoms; iv) an aralkyl of 7 to 12 carbon atoms; v) phenyl; vi) substituted phenyl 74 z ZI Z q wherein Zi, Zji, Ziii, Ziv and Zv are each independently selected from -NO 2
-CN,
1
-SO
3 H, a hydrogen atom, halogen, methyl, -ORx, wherein Rx is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl; vii) a detectable label molecule; or viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive; wherein Q 1 is SO 2 or provided when Q1 is CN, then X is absent; wherein R 4 is
H;
an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched; wherein Rs is a substituted phenyl wherein Zi, Zi, Zji, Ziv and Zv are each independently selected from -NO 2 -CN,
C(=O)-R
1
-SO
3 H, a hydrogen atom, halogen, methyl, -ORx, wherein Rx is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group; wherein R 6 is
H;
an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched; wherein T is O or S, and pharmaceutically acceptable salts thereof.
The invention is further directed to useful lipoxin compounds having the formula
(V)
x 4 0O wherein X is R 1
OR
1 or SRi; wherein R, is a hydrogen atom; (ii) an alkyl of 1 to 8 carbon atoms, inclusive, which may be straight chain or branched; (iii) a cycloalkyl of 3 to 10 carbon atoms; (iv) an aralkyl of 7 to 12 carbon atoms; phenyl; (vi) substituted phenyl Zi
Z,
Z, Ziv wherein Zi, Zi, Zi 1 Ziv and Zv are each independently selected from -NO 2 -CN,
C(=O)-R
1
-SO
3 H, a hydrogen atom, halogen, methyl, -ORx, wherein Rx is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl; (vii) a detectable label molecule; or (viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive; wherein Q 1 is SO 2 or provided when Qi is CN, then X is absent; wherein R 4 is
H;
an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched; wherein R 5 is substituted phenyl Z, Ziv wherein Zi, Zin, Zaii, Zjv and Zv are each independently selected from -NO 2 -CN,
-SO
3 H, a hydrogen atom, halogen, methyl, -ORx, wherein R, is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group; wherein R 6 is
H;
an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched; and pharmaceutically acceptable salts thereof.
In preferred embodiments, X is OR 1 wherein R 1 is a hydrogen atom, an alkyl group of 1 to 4 carbon atoms or a pharmaceutically acceptable salt, Q 1 is C=0, R 2 and R 3 if present, are hydrogen atoms, R 4 is a hydrogen atom or methyl,
Q
3 and Q 4 if present, are both O, R 6 if present, is a hydrogen atom, Y1, if present, is OH, T is O and R 5 is a substituted phenyl, e.g., 00
O
00 wherein Zi, Z 1 Zi, Zi, and Z, are each independently selected from -NO 2
-CN,
S-C(=O)-R
1
-SO
3 H, a hydrogen atom, halogen, methyl, -ORx, wherein Rx is 1 to 8 to carbon atoms, inclusive, which may be a straight chain or branched, and 0 5 hydroxyl.
In certain embodiments for Rs, para-fluorophenyl and/or unsubstituted phenyl are excluded, 15-epi-16-(para-fluoro)-phenoxy-LXA 4 16-(parafluoro)-phenoxy-LXA 4 15-epi-16-phenoxy-LXA 4 or 16-phenoxy-LXA 4 The compounds encompassed by U.S. Patent 5,441,951 are excluded from certain aspects of the present invention.
In still another aspect, the present invention is directed to pharmaceutical compositions including compounds having the above-described formulae and a pharmaceutically acceptable carrier. In one embodiment, a preferred compound is In a preferred embodiment the invention provides a method for treating phospholipase D (PLD) initiated polymorphoneutrophil (PMN) inflammation in a subject, comprising administering to the subject an effective anti-inflammatory amount of a lipoxin anaolog having the formula OH OH o wherein R 1 is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof, such that PLD initiated polymorphoneutrophil (PMN) inflammation is treated in a subject.
According to another aspect of the present invention, there is provided a method for treating phospholipase D (PLD) initiated superoxide generation or degranulation in a subject, comprising administering to the subject an effective anti-PLD amount of a lipoxin analog having the formula OH OH o wherein R 1 is a hydrogen atom, a pharmaceutically acceptable ester and a pharmaceutically acceptable salts thereof, such that PLD initiated superoxide generation or granulation is treated in a subject.
In a preferred embodiment, the pharmaceutical carrier is not a ketone, e.g., acetone.
In preferred embodiments, Y 1 is a hydroxyl and the carbon bearing the hydroxyl can have an R or S configuration. In most preferred embodiments, the chiral carbon bearing the hydroxyl group, Y 1 is designated as a lipoxin as is known in the art.
In certain embodiments the chirality of the carbons bearing the R 2
R
3
Q
3 and Q 4 groups can each independently be either R or S. In preferred embodiments, Q 3 and Q 4 have the chiralities shown in structures II, III, IV or V.
In preferred embodiments, R 4 is a hydrogen. In other preferred embodiments, R 6 is a hydrogen.
Additionally, R 5 can be a substituted or unsubstituted, branched or unbranched alkyl group having between 1 and about 6 carbon atoms, preferably between 1 and 4 carbon atoms, most preferably between 1 and 3, and preferably one or two carbon atoms. The carbon atoms can have substituents which include halogen atoms, hydroxyl groups, or ether groups.
The compounds useful in the present invention can be prepared by the following synthetic scheme:
HQ
4 SQI~x R4 e3Si R3 catalytic hydrogenation Br T Re Y, HQ4 Q3H R2 \x .Tr Rs R3 R6 Yi wherein X, Q 1
Q
3
Q
4
R
3 R4, R, Y, and T are as defined above. Suitable methods known in the art to can be used to produce each fragment. For example, the acetylenic fragment can be prepared by the methods discussed in Nicolaou, K.C. et al.
(1991) Angew. Chem. Int. Ed. Engl. 30:1100; Nicolaou, K.C. et al. (1989) J. Org. Chem.
54:5527; Webber, S.E. et al. (1988) Adv. Exp. Med. Biol. 229:61; and U.S. Patent 5,441,951. The second fragment can be prepared by the methods of Raduchel, B. and Vorbruggen, H. (1985) Adv. Prostaglandin Thromboxane Leukotriene Res. 14:263.
A "lipoxin analog" shall mean a compound which has an "active region" that functions like the active region of a "natural lipoxin", but which has a "metabolic transformation region" that differs from natural lipoxin. Lipoxin analogs include compounds which are structurally similar to a natural lipoxin, compounds which share the same receptor recognition site, compounds which share the same or similar lipoxin metabolic transformation region as lipoxin, and compounds which are art-recognized as being analogs of lipoxin. Lipoxin analogs include lipoxin analog metabolites. The compounds disclosed herein may contain one or more centers of asymmetry. Where asymmetric carbon atoms are present, more than one stereoisomer is possible, and all possible isomeric forms are intended to be included within the structural representations shown. Optically active and isomers may be resolved using conventional techniques known to the ordinarily skilled artisan. The present invention is intended to include the possible diastereiomers as well as the racemic and optically resolved isomers.
The terms "corresponding lipoxin" and "natural lipoxin" refer to a naturallyoccurring lipoxin or lipoxin metabolite. Where an analog has activity for a lipoxinspecific receptor, the corresponding or natural lipoxin is the normal ligand for that receptor. For example, where an analog is a LXA 4 specific receptor on differentiated cells, the corresponding lipoxin is LXA 4 Where an analog has activity as an antagonist to another compound (such as a leukotriene), which is antagonized by a naturally-occurring lipoxin, that natural lipoxin is the corresponding lipoxin.
"Active region" shall mean the region of a natural lipoxin or lipoxin analog, which is associated with in vivo cellular interactions. The active region may bind the "recognition site" of a cellular lipoxin receptor or a macromolecule or complex of macromolecules, including an enzyme and its cofactor. Preferred lipoxin A 4 analogs have an active region comprising C 5 of natural lipoxin A 4 Preferred lipoxin B 4 analogs have an active region comprising C5-C14 of natural lipoxin B4.
The term "recognition site" or receptor is art-recognized and is intended to refer generally to a functional macromolecule or complex of macromolecules with which certain groups of cellular messengers, such as hormones, leukotrienes, and lipoxins, must first interact before the biochemical and physiological responses to those messengers are initiated. As used in this application, a receptor may be isolated, on an intact or permeabilized cell, or in tissue, including an organ. A receptor may be from or in a living subject, or it may be cloned. A receptor may normally exist or it may be induced by a disease state, by an injury, or by artificial means. A compound of this invention may bind reversibly, irreversibly, competitively, noncompetitively, or uncompetitively with respect to the natural substrate of a recognition site.
The term "metabolic transformation region" is intended to refer generally to that portion of a lipoxin, a lipoxin metabolite, or lipoxin analog including a lipoxin analog metabolite, upon which an enzyme or an enzyme and its cofactor attempts to perform one or more metabolic transformations which that enzyme or enzyme and cofactor normally transform on lipoxins. The metabolic transformation region may or may not be susceptible to the transformation. A nonlimiting example of a metabolic transformation region of a lipoxin is a portion of LXA 4 that includes the C-13,14 double bond or the C-15 hydroxyl group, or both.
The term "detectable label molecule" is meant to include fluorescent, phosphorescent, and radiolabeled molecules used to trace, track, or identify the compound or receptor recognition site to which the detectable label molecule is bound.
The label molecule may be detected by any of the several methods known in the art.
The term "labeled lipoxin analog" is further understood to encompass compounds which are labeled with radioactive isotopes, such as but not limited to tritium 3 deuterium 2 carbon 4 or otherwise labeled fluorescently).
The compounds of this invention may be labeled or derivatized, for example, for kinetic binding experiments, for further elucidating metabolic pathways and enzymatic mechanisms, or for characterization by methods known in the art of analytical chemistry.
The term "inhibits metabolism" means the blocking or reduction of activity of an enzyme which metabolizes a native lipoxin. The blockage or reduction may occur by covalent bonding, by irreversible binding, by reversible binding which has a practical effect of irreversible binding, or by any other means which prevents the enzyme from operating in its usual manner on another lipoxin analog, including a lipoxin analog metabolite, a lipoxin, or a lipoxin metabolite.
The term "resists metabolism" is meant to include failing to undergo one or more of the metabolic degradative transformations by at least one of the enzymes which metabolize lipoxins. Two nonlimiting examples of LXA 4 analog that resists metabolism are 1) a structure which can not be oxidized to the 15-oxo form, and 2) a structure which may be oxidized to the 15-oxo form, but is not susceptible to enzymatic reduction to the 13,14-dihydro form.
The term "more slowly undergoes metabolism" means having slower reaction kinetics, or requiring more time for the completion of the series of metabolic transformations by one or more of the enzymes which metabolize lipoxin. A nonlimiting example of a LXA 4 analog which more slowly undergoes metabolism is a structure which has a higher transition state energy for C-15 dehydrogenation than does
LXA
4 because the analog is sterically hindered at the C-16.
.The term "tissue" is intended to include intact cells, blood, blood preparations such as plasma and serum, bones, joints, muscles, smooth muscles, and organs.
The term "halogen" is meant to include fluorine, chlorine, bromine and iodine, or fluoro, chioro, bromo, and iodo. In certain aspects, the compounds of the invention do not include halogenated compounds, fluorinated compounds.
The term "subject"" is intended to include living organisms susceptible to conditions or diseases caused or contributed to by inflammation, inflammatory responses, vasoconstriction, and myeloid suppression. Examples of subjects include humans, dogs, cats, cows, goats, and mice. The term subject is fur-ther intended to include transgenic species.
When the compounds of the present invention are administered as pharmaceuticals, to humans and mammals, they can be given per se or as a pharmaceutical composition containing, for example, 0. 1 to 99.5% (more preferably, to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.
The phrase "Pharmaceutically acceptable carrier" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a compound(s) of the present invention within or to the subject such that it can perform its intended function. Typically, such compounds are carried or transported from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations.
In certain embodiment, the compounds of the present invention may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases. The term "pharmaceutically acceptable salts" in these instances refers to the relatively non-toxic, inorganic and organic base addition salts of compounds of the present invention. These salts can likewise be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation, withammonia, or with a pharmaceutically acceptable organic primary, secondary or tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like.
Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like.
The term "pharmaceutically acceptable esters" refers to the relatively non-toxic, esterified products of the compounds of the present invention. These esters can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a suitable esterifying agent. Carboxylic acids can be converted into esters via treatment with an alcohol in the presence of a catalyst. The term is further intended to include lower hydrocarbon groups capable of being solvated under physiological conditions, alkyl esters, methyl, ethyl and propyl esters. In a preferred embodiment, the ester is not a methyl ester (See, for example, Berge et al., supra.).
Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
Examples of pharmaceutically acceptable antioxidants include: water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
Formulations of the present invention include those suitable for intravenous, oral, nasal, topical, transdermal, buccal, sublingual, rectal, vaginal and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 per cent to about 70 per cent, most preferably from about 10 per cent to about 30 per cent.
Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient A compound of the present invention may also be administered as a bolus, electuary or paste.
r In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; solution retarding agents, such as paraffin; absorption accelerators, such as quaternary ammonium compounds; wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; absorbents, such as kaolin and bentonite clay; lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active compound in a polymer matrix or gel.
Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention.
Pharmaceutical compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form.
Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide.
Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
The preparations of the present invention may be given orally, parenterally, topically, or rectally. They are of course given by forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection,
I
inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Intravenous injection administration is preferred.
The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasteral injection and infusion.
The phrases "systemic administration," "administered systematically," "peripheral administration" and "administered peripherally" as used herein mean the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.
Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of ordinary skill in the art.
Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
In general, a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.
Generally, intravenous and subcutaneous doses of the compounds of this invention for a patient, when used for the indicated analgesic effects, will range from about 0.0001 to about 100 mg per kilogram of body weight per day, more preferably from about 0.01 to about 50 mg per kg per day, and still more preferably from about 0.1 to about 40 mg per kg per day. For example, between about 0.01 microgram and 20 micrograms, between about 20 micrograms and 100 micrograms and between about 10 micrograms and 200 micrograms of the compounds of the invention are administered per 20 grams of subject weight.
If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
While it is possible for a compound of the present invention to be administered alone, it is preferable to administer the compound as a pharmaceutical composition.
Methods Materials.
PSDP and PSMP were prepared by total organic synthesis and characterized by their physical chemical and biological properties (Takano, Clish, C.
Gronert, Petasis, and Serhan, C. N. (1998) Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered lipoxinA 4 and novel lipoxin B 4 stable analogues. J. Clin. Invest. 101, 819-826; Levy, B.
Petasis, N. and Serhan, C. N. (1997) Polyisoprenyl phosphates in intracellular signaling. Nature 389, 985-989). LTB 4 was purchased from Cayman Chemical (Ann Arbor, MI), cabbage PLD (cPLD), FDP, squalene, lysis buffer reagents and cytochrome c were from Sigma Chemical Co. (St. Louis, MO), and PC and PA were from Avanti Polar Lipids (Alabaster, AL). The integrity and concentration of each bioactive lipid was assessed just prior to each series of experiments by UV analysis (eicosanoids and analogs) and phosphorus determinations (polyisoprenyl phosphates) (Takano, Clish, C. B., Gronert, Petasis, and Serhan, C. N. (1998) Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered lipoxin A 4 and novel lipoxin B 4 stable analogues. J. Clin. Invest. 101, 819-826; Levy, B.
Petasis, N. and Serhan, C. N. (1997) Polyisoprenyl phosphates in intracellular signaling. Nature 389, 985-989).
Human PMN Peripheral venous blood (-180 ml) was obtained by venipuncture from healthy volunteers who denied taking any medication for at least two weeks and had given written informed consent to a protocol approved by Brigham and Women's Hospital's Human Research Committee. PMN were isolated from whole blood and steady state labeled with [y- 2 P]ATP (40 pCiml 90 min, 37°C) as in (Levy, B. Petasis, N. and Serhan, C.
N. (1997) Polyisoprenyl phosphates in intracellular signalling. Nature 389, 985-989).
Labeled PMN were resuspended (20 x 10'ml PBS with I mM CaCI 2 pH 7.40) and exposed to LTB 4 (100 nM), 15-epi-LXa (100 nM) or vehicle EtOH) for 0 to 300 seconds (37C). From each incubation, aliquots were removed at indicated intervals to determine the radiolabeling ofnonsaponifiable lipids (10 12 x 106 PMN) and PLD activity (1 1.25 x 106 PMN). Materials present in each incubation were saponified, extracted and separated by TLC with phosphoimaging (model 425E and integration software; Molecular Dynamics), which was used for PSDP mass determination as in ref 22.
Preparation of recombinant human PLDlb.
Spodoptera frugiperda (Sf9) cells were cultured in suspension at 2 x 10 to 2 x 10 6 cells/ml TC100 medium supplemented with 10% fetal calf serum (Gibco). A cDNA encoding human PLDlb (cloned from placental tissue) was inserted into the transfer vector pACGHLT (Pharmingen) downstream of, and in frame with, vector sequences encoding glutathione-S-transferase (GST), hexahistidine, a protein kinase A phosphorylation site and a thrombin cleavage site. The GST-hPLDlb construct was cotransfected into Sf9 cells with linearized, polyhedrin-minus AcMNPV DNA, Bac-N-Blue, according to the supplier's instructions (Invitrogen). Homologous recombination between linearized virus and the transfer vector restored the function of essential viral gene ORF1629 to yield infectious, recombinant virus. After two rounds of plaque-purification, recombinant virus was amplified by large scale infections of Sf9 cells until a titer of 8 x 10' pfu/ml was obtained. To generate GST-hPLDlb, 500 ml of Sf9 cells at 2 x 106 cells/ml were infected with virus at a multiplicity of infection of 10:1.
Cells were harvested 72 hours post-infection, lysed and the expressed GST-hPLDlb purified on glutathione agarose beads, according to supplier's instructions (Pharmingen).
The purified recombinant protein was identified by immunoreactivity with goat anti-GST pAb (Amersham Pharmacia Biotech) and rabbit pAb raised against the PLD consensus peptide sequence GSANIN (gift of P. Parker, ICRF, London, UK), and by activity in an in vitro PLD assay (24).
PLD activity and superoxide anion generation.
Lysates were generated from cells at rest or after exposure to agonist using a lysis buffer comprised of 0.1 M Hepes (pH 0.7 mM sodium orthovanadate, 10 pM pnitrophenylphosphate, 10 mM EGTA, 5.5% triton X-100, 0.5 M B-glycerophosphate, mM phenylmethylsulfonylfluoride, 0.1 mM ammonium molybdate, 12 mM DFP, 5 jgml" 'leupeptin, 2 pgml aprotinin and 7 ugml' pepstatin A (as in ref25) and utilized for bioassay.
PMN lysates (90-130 ig protein), purified phospholipase D (3 30 units) (EC Sigma Chemical Co.) or recombinant hPLD1b were warmed (37*C for mammalian enzyme and 30*C for cabbage, 3 min) and exposed to PSDP, PSMP or FDP 1000 nM, 5 min, 37C or 30°C) followed by PC (0.5 to 5 mM) in Tris-HCl (50 mM, pH 7.5) with CaC1, (30 mM). Reactions were terminated at 30 second intervals (0-90 seconds) with Tris-HCl (1 M) plus EDTA (50 mM). Choline release was quantitated as in ref 26.
Freshly isolated human PMN (1-3 x 106 PMN/ml HBSS 1.6 mM CaC12) were incubated (5 min, 37°C) in the presence of 15-epi-LXa (1-100 nM) or vehicle (0.1% ethanol), and then exposed (10 min) to LTB 4 (100 nM) in the presence of cytochrome c (7 mg/ml). Superoxide anion generation was determined as in ref22.
Statistical Analysis.
Results are expressed as the mean S.E. and statistical significance was evaluated using the Student's t test Results Leukotriene B 4 stimulates rapid remodeling of PIPP: Degradation of PSDP.
Leukotriene B 4 interacts with its receptor to rapidly activate phospholipases and signal cellular responses (Yokomizo, Izumi, Chang, Takuwa, and Shimizu, T. (1997) A G-protein-coupled receptor for leukotriene B 4 that mediates chemotaxis.
Nature 387, 620-624). To determine if LTB 4 receptor activation lead to remodeling of PIPP and specifically PSDP, cellular phosphate pools were steady state labeled with [y- "P]-ATP (see Methods) and exposed to either LTB 4 (100 nM) or vehicle ethanol) alone. Aliquots were removed at timed intervals from 0 to 300 sec (37*C) and nonsaponifiable phosphorylated lipids were isolated and quantitated by phosphoimager for [32] incorporation. PSDP levels in unstimulated PMN are -1.7 nmoles/10 7 PMN nM) (Levy, B. Petasis, N. and Serhan, C. N. (1997) Polyisoprenyl phosphates in intracellular signalling. Nature 389, 985-989). PSDP and presqualene monophosphate (PSMP), but not farnesyl diphosphate (FDP), incorporated [32P] from ATP, consistent with recent evidence (Levy, B. Petasis, N. and Serhan, C. N. (1997) Polyisoprenyl phosphates in intracellular signalling. Nature 389, 985-989). LTB 4 initiated a rapid (evident within 30 sec) (Figure 1B) and statistically significant decrease in 2
P]-PSDP
within 60 sec (Figure 1C). Within the ensuing 270 sec, 2 P]-PSDP levels returned to baseline amounts Changes in 32 P]-PSDP after LTB 4 receptor activation reflected changes in PSDP mass. These results confirmed that PSDP was present in PMN (Levy, B. Petasis, N. and Serhan, C. N. (1997) Polyisoprenyl phosphates in intracellular signalling. Nature 389, 985-989) and indicated that LTB 4 initiated a marked decrement in PSDP (Figure 1) with a time course of PIPP remodeling concurrent with
LTB
4 kinetics of cellular activation (Borgeat, and Naccache, P. H. (1990) Biosynthesis and biological activity of leukotriene B 4 Clin. Biochem. 23,459-468; Levy, B. D., Petasis, N. and Serhan, C. N. (1997) Polyisoprenyl phosphates in intracellular signalling. Nature 389, 985-989).
LX analog switches the LTB 4 program to enhance PSDP.
Both LXA 4 and some 15-epi-LXA 4 stable analogs act at the LXA 4 receptor on PMN, inhibiting infiltration in vivo. To determine if LX and 15-epi-LX mediate inhibitory actions via PIPP signaling, the impact of a 15-epi-LXA 4 analog (100 nM, 5 min, 37 0 C) on LTB 4 (100 nM) -stimulated changes in PSDP was examined using 32 labeling of PMN lipids (vide supra, in parallel incubations). Alone, LXa did not affect the rate of PIPP remodeling (Figure 1B). Of interest, exposure to
LTB
4 in the presence of equimolar 15-epi-LXa not only prevented the LTB 4 initiated decrease in PSDP, but additionally stimulated a significant increase in PSDP at 60 sec (Figure 1C). PSDP levels continued to rise for at least 300 sec after exposure to LTB 4 (Figure 1B). Native LXA 4 and its related LXA 4 receptor agonist, 16phenoxy-LXA 4 -methyl ester, gave qualitatively similar responses as 15-epi-LXa with a rank order of potency of 15-epi-LXa 16-phenoxy-LXA 4
LXA
4 with 15-epi-LXa 1-2 orders of magnitude more potent. These results indicate that 15-epi-LXa, which inhibits
LTB
4 responses in vivo (Takano, Fiore, Maddox, J. Brady, H. Petasis, N. A., and Serhan, C. N. (1997) Aspirin-triggered 15-epi-lipoxin A 4
(LXA
4 and LXA 4 Stable analogues are potent inhibitors of acute inflammation: Evidence for anti-inflammatory receptors. J. Exp. Med 185, 1693-1704), dramatically switches LTB 4 -initiated PIPP signaling. Moreover, increases in PSDP levels evoked by coactivation of the LXA 4 and
LTB
4 receptors indicate that the time course of PSDP accumulation correlated with regulation of LTB4's actions by LX and 15-epi-LXa (vide infra).
inhibits LTB 4 -stimulated PLD activity and 02 generation.
LTB
4 -stimulated PLD activity is associated with morphologic change, degranulation and 0;2 production in PMN (Olson, S. and Lambeth, J. D. (1996) Biochemistry and cell biology of phospholipase D in human neutrophils. Chem. Phys.
Lipids 80, 3-19; Zhou, Chabot-Fletcher, Foley, J. Sarau, H. Tzimas, M.
Winkler, J. and Torphy, T. J. (1993) Association between leukotriene B 4 -induced phospholipase D activation and degranulation of human neutrophils. Biochem.
Pharmacol. 46, 139-148). To determine whether LT and LX-mediated remodeling of PIPP correlates with specific cell signaling events, PLD activity was monitored in cell lysates from the same incubations used in Figure 1. LTB4 gave increases in PLD activity that were maximal by 60 sec (Figure 2A). These values for LTB 4 and PLD are consistent with those of earlier reports (Gomez-Cambronero, J. (1995) Immunoprecipitation of a phospholipase D activity with antiphosphotyrosine antibodies. J. Interferon Cytokine Res.
877-885; Zhou, Chabot-Fletcher, Foley, J. Sarau, H. Tzimas, M. N., Winkler, J. and Torphy, T. J. (1993) Association between leukotriene B 4 -induced phospholipase D activation and degranulation of human neutrophils. Biochem.
Pharmacol. 46, 139-148). In the presence of 15-epi-LXa, LTB 4 -stimulated PLD activity was inhibited at 60 sec (Figure 2A&B). 15-epi-LXa also potently inhibited
LTB
4 -stimulated O' generation (Figure 2C). Together, these findings indicate that ligand-receptor interaction that signals opposing cellular responses gave an inverse relationship between 2 P]-PSDP levels and PLD activity, demonstrating that PSDP could regulate PLD.
Direct inhibition of both plant and mammalian PLD.
To determine whether polyisoprenyl phosphates act directly on PLD, PSDP and closely related lipids were incubated with purified plant enzyme (EC 3.1.4.4; Vm 0.29 nmoles/sec, Km 1.4 mM). As seen in Figure 3, PSDP inhibited cPLD in a concentration-dependent fashion (10 to 1000 nM) with a Ki of 20 nM ((PSDP) 10 nM).
Lineweaver-burk analyses (Figure 3) were consistent with a competitive inhibition model.
Closely related lipids, such as PSMP (minus only one phosphate), showed a greater than 100-fold loss in inhibitory potency compared to PSDP (Table Comparable inhibition was not evident with other polyisoprenoids FDP and squalene) or a PLD product It was determined whether PSDP could also inhibit mammalian PLD by determining recombinant human PLD1b kinetics in vitro with PSDP. The recombinant enzyme (Vm 0.36 nmoles/sec, Km 13.8 mM) was also dramatically inhibited by PSDP with a Ki of 6 nM (Table I).
TABLE 1. PSDP selectively inhibitsphospholipase D: structure activity relationship with related endogenous lipids' Lipid Enzyme K. (mM) V m cPLD 1.4 0.29 rhPLDlb 13.8 0.36 Kp (mrM) V.,a K(nM) Presqualene diphosphate cPLD 2.1 0.25 rhPLDlb 3.1 0.03 6 Presqualene monophosphate cPLD 3.1 0.36 3210 Squalene cPLD 4.0 0.46 0 Farnesyl diphosphate cPLD 0.9 0.25 0 Phosphatidic acid cPLD 3.6 0.43 0 aEnzyme kinetics for PLD were determined in the presence of PSDP or related lipids.
Purified or isolated PLD (3u cPLD or 0.3u rhPLDlb/reaction) activity in the presence of the test compounds was determined as described in Fig. 3 legend K, was calculated using the formula: Slope K/Vm Absence of inhibition is reported as =0.
Because PLD activation occurs in vivo in the presence of many cofactors which modulate its activity, it was also determined the impact of PSDP on PLD activity in PMN lysates. Sixty seconds following LTB,, PSDP levels decreased Figure 1) and PLD activity was maximal (Figure Addition of PSDP (100 nM) to PMN lysates at this time sec, LTB 4 100 nM) gave 89.5 9.7% inhibition of PLD activity. Collectively, these results indicated that PSDP was a potent inhibitor of both plant and mammalian PLD's and establish a critical role for both the terminal phosphate and the isoprenoid chain length in PSDP's action with PLD activity.
The present results characterize PIPP remodeling as a rapid switch for "stop" signaling used by an extracellular regulator of PMN responses. LTB 4 receptor activation initiated a rapid and transient decrease in PSDP (Figure 1) that coincided temporally with increased PLD activity (Figure As PSDP remodeling returned toward baseline values, PLD activity decreased, revealing an inverse relationship and suggesting a role for PSDP in the regulation of this pivotal lipid-modifying enzyme. Cells exposed to LTB 4 and an
LXA
4 receptor agonist (15-epi-LXa) showed a dramatic switch in PSDP remodeling to give increased 32 P]-PSDP and marked inhibition of both PLD activity and superoxide anion generation (Figures 1 In addition, synthetic PSDP was a selective and potent inhibitor of isolated PLD (Figure 3, Table a property not shared by other closely related lipids. Taken together, the reciprocal relationship between PSDP levels and PLD activity as well as direct inhibition of recombinant human PLDlb, purified cPLD and PLD activity in PMN lysates support a role for PSDP as an endogenous lipid regulator of PMN PLD activity. The different temporal profiles of PIPP remodeling initiated upon receptor activation by PMN ligands with opposing actions stimulation and inhibition) suggest that PIPP remodeling and PSDP itself may serve as important components in intracellular signaling, in particular as "stop" signals.
Cholesterol is not a biosynthetic product in PMN, as they lack a mixed function oxidase and cyclase necessary for its endogenous formation from acetate (Shechter, I., Fogelman, A. and Popjak, G. (1980) A deficiency of mixed function oxidase activities in the cholesterol biosynthetic pathway of human granulocytes. J. Lipid Res. 21, 277-283). In view of the present findings, the resultant biosynthetic termination at squalene in PMN suggests that products such as squalene's direct precursor, PSDP, carries functions distinct from cholesterol biosynthesis. Hence, it is likely that the PIPP signaling pathway uncovered in human PMN may extend to other cell types. In addition to dietary influences known to impact mevalonate and polyisoprenyl phosphate biosynthesis, PSDP formation is also actively regulated by soluble immune stimuli and growth factors (Figure 1B,C). Granulocyte/macrophage-colony stimulating factor, for example, increases PSDP remodeling in PMN whereas the chemotactic peptide, fMLP, triggers (within seconds) rapid decrements in PSDP and reciprocal increments in PSMP that return to baseline within 5-10 minutes (Levy, B. Petasis, N. and Serhan, C. N.
(1997) Polyisoprenyl phosphates in intracellular signalling. Nature 389, 985-989). This time course of PIPP remodeling is similar in magnitude and extent to LTB 4 -initiated decrements in PSDP (Figure 1B C) and correlates well with the time course of activating neutrophil responses such as 02O generation, which is inhibited by PSDP. The presence of PSDP in peripheral blood PMN despite their inability to generate cholesterol from endogenous sources, its rapid remodeling in response to receptor-mediated inflammatory stimuli of diverse classes of receptor agonist, and its ability to inhibit PLD activity and NADPH oxidase at nanomolar levels are supportive evidence for a role for PSDP as a novel negative intracellular signal. Thus, this newly uncovered PIPP signaling might function to decrease negative signal levels, in contrast to the well-appreciated phosphotidylinositol signaling pathways (reviewed in Pettit, T. Martin, Horton, T., Liossis, Lord, J. and Wakelam, M. J. 0. (1997) Diacylglycerol and phosphatidate generated by phospholipases C and D, respectively, have distinct fatty acid compositions and functions. J. Biol. Chem. 272, 17354-17359) that, when activated, rapidly generate positive intracellular stimuli inositol trisphosphate, diacylglycerol Ca2+).
Aspirin, the lead non-steroidal anti-inflammatory drug, also effects cholesterol biosynthesis by mechanisms that remain to be completely elucidated (Rabinowitz, J. L., Baker, D. Villanueva, T. Asanza, A. and Capuzzi, D. M. (1992) Liver lipid profiles of adults taking therapeutic doses of aspirin. Lipids 27, 311-314). Beyond its well-appreciated inhibition of cyclooxygenase (COX), aspirin can pirate this system to set in place an anti-inflammatory circuit generating 15-epi-LX, carbon 15-R-epimers of the natural 15-S-containing-LX, during cell-cell interactions by aspirin-acetylated COX-2 and (Figure 1A and Chiang, Takano, Clish, C. Petasis, N. Tai, and Serhan, C. N. (1998) Aspirin-triggered 15-epi-lipoxin A 4 (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific LXA ELISA. J. Pharmacol Exper. Ther. 287, 779-790). These aspirin-triggered LX carry anti-inflammatory and anti-proliferative properties (Claria, and Serhan, C. N.
(1995) Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad Sci. 92, 9475-9479; Serhan, C.
N. (1997) Lipoxins and Novel Aspirin-Triggered 15-epi-Lipoxins: A Jungle of Cell-Cell Interactions or a Therapeutic Opportunity? Prostaglandins 53, 107-137) and may mediate a component of aspirin's beneficial therapeutic actions. As observed in the present experiments, LXA 4 receptor activation by a 15-epi-LX mimetic reversed PSDP remodeling initiated by LTB 4 receptors, leading to increases in PSDP levels (Figure 1).
Since the 15-epi-LXa inhibited both PLD activity and superoxide anion generation (Figure these results implicate PIPP remodeling as a component of the cellular basis for aspirin's inhibition of excessive inflammatory responses. In addition to regulating LTB4's stimulatory actions, this novel mechanism of inhibition of LTB 4 receptor signaling may also play broader roles in host defense, as this receptor was recently identified as a co-receptor for HIV-1 (Owman, Garzino-Demo, Cocchi, Popovic, Sabirsh, and Gallo, R. (1998) The leukotriene B 4 receptor functions as a novel type of coreceptor mediating entry of primary HIV-1 isolates into CD4-positive cells. Proc. Natl.
Acad Sci. 95, 9530-9534).
Hydrolysis of PC to PA by PLD appears crucial in transmembrane signaling by a wide range of receptor classes during PMN activation (Olson, S. and Lambeth, J. D.
(1996) Biochemistry and cell biology of phospholipase D in human neutrophils. Chem.
Phys. Lipids 80, 3-19). Both G-protein linked receptors and receptor tyrosine kinases activate PLD. In leukocytes, several factors including PKCa (in a kinase-independent manner) and increased intracellular calcium can activate PLD1 (Exton, J. H. (1997) New developments in phospholipase D. J. Biol. Chem. 272, 15579-15582). FMLP-stimulated PLD activity in PMN is increased by membrane association of the ADP-ribosylation factor (ARF) and small GTPase RhoA (Fensome, Whatmore, Morgan, Jones, and Cockcroft, S. (1998) ADP-ribosylation factor and Rho proteins mediate fMLPdependent activation of phospholipase D in human neutrophils. J. Biol. Chem. 273, 13157-13164). Of considerable interest here, PSDP directly inhibited recombinant hPLDlb in the absence of regulatory proteins (see Table These results suggest that PSDP may inhibit PLD at its catalytic center and is likely to act at other PLD isoforms, such as PLD1a and PLD2 isoforms where the catalytic centers are conserved. PSDP's ability to serve as an endogenous inhibitor of PLD likely results from PSDP's unique three-dimensional and physical chemical properties which might now serve as a template for the preparation of more potent PLD inhibitors by design to fulfill the structure activity relationship uncovered here.
Regulation of PMN activation in complex host responses is controlled in part by soluble mediators and, in particular, by autacoids with opposing actions (Serhan, C. N., Haeggstrom, J. and Leslie, C. C. (1996) Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 10, 1147-1158), such as LT and LX, that here gave markedly different profiles for PIPP remodeling (Figure In most cell types, PSDP is appreciated as a biosynthetic intermediate in cholesterol production by microsomal squalene synthase, which catalyzes head-to-head condensation of two FDP (Jarstfer, M. Blagg, B. S. Rogers, D. and Poulter, C. D. (1996) Biosynthesis of squalene. Evidence for a tertiary cyclopropylcarbinyl cationic intermediate in the rearrangement ofpresqualene diphosphate to squalene. J. Amer. Chem. Soc. 118, 13089- 13090). Ligand-operated rapid remodeling of PSDP in PMN is likely to occur in membranes in proximity to LTB 4 and LXA 4 receptors and suggests a non-microsomal pool of PSDP that may result from 1) novel biosynthetic and/or metabolic pathways or 2) intracellular trafficking of PIPP with proteins from endoplasmic reticulum to membrane domains. Incorporation of from ATP into PSDP but not FDP (see Results) is further evidence in support of a novel route for PSDP formation in PMN. The present results suggest that PIPP remodeling is linked to cell surface receptor activation and is involved in the intracellular transmission of extracellular ligands with opposing biological actions.
In the present working model, a "negative lipid signal" PSDP) is held at a set point, like a ratchet, in "resting" cells. Incoming positive signals (LTB 4 fMLP, etc.) initiate the degradation and inactivation of this inhibitory lipid remodeling PSDP to the inactive monophosphate species, PSMP) (Figure lA and ref22). Thus, PIPP remodeling enables mounting of intracellular positive signals that threshold for activation of select cellular processes. This type of signaling may explain the selectivity and tight coupling required by agonists such as LTB 4 that stimulate highly specialized functional responses of PMN such as chemotaxis, granule mobilization and superoxide anion generation. The extent to which this model of cell signaling, namely receptor-initiated degradation of negative lipid signals, occurs with other receptors and cell types remains for further studies.
In summary, ligand-operated rapid remodeling of PIPPs in human PMN and direct inhibition of PLD activity at nanomolar levels support a role for PSDP as an intracellular signal and provide novel intracellular targets by which PSDP can regulate cellular responses (Levy, B. Petasis, N. and Serhan, C. N. (1997) Polyisoprenyl phosphates in intracellular signalling. Nature 389, 985-989). Given the wide occurrence of PIPP and critical role of PLD in the plant and animal kingdoms, PIPP remodeling and direct inhibition ofPLD first established here in human PMN may have wider implications in cell signaling in other cell types and species (Martin, Saqib, K. M., Hodgkin, M. Brown, F. Pettit, T. Armstrong, and Wakelam, M. J. O.
(1997) Role and regulation ofphospholipase D signalling. Biochem. Soc. Trans. 1157-1160; Bach, T. J. (1995) Some new aspects ofisoprenoid biosynthesis in plants -a review. Lipids 30, 191-202). The present results are the first to show direct inhibition of a phospholipase involved in signal transduction by an endogenous intracellular lipid and set forth a new paradigm for lipid-protein interactions in the control of cellular responses, namely receptor-initiated degradation of a repressor lipid, that is also subject to regulation by aspirin ingestion via the actions of aspirin-triggered 15-epimer LX. Together, these results suggest that PIPP signaling pathways might also be of interest in pharmacologic interventions and specifically that the conformation of PSDP can serve as a template for
I
design of novel inhibitors.
References 1. Weissmann, Smolen, J. and Korchak, H. M. (1980) Release of inflammatory mediators from stimulated neutrophils. N. Engl. J. Med. 303, 27-34 2. Serhan, C. Haeggstrom, J. and Leslie, C. C. (1996) Lipid mediator networks in cell signaling: update and impact of cytokines. FASEBJ. 10, 1147- 1158 3. Weiss, S. J. (1989) Tissue destruction by neutrophils. N. Engl. J. Med. 320, 365- 376 4. Serhan, C. N. (1994) Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim. Biophys. Acta 1212, 1-25 Borgeat, and Naccache, P. H. (1990) Biosynthesis and biological activity of leukotriene B 4 Clin. Biochem. 23, 459-468 6. Yokomizo, Izumi, Chang, Takuwa, and Shimizu, T. (1997) A Gprotein-coupled receptor for leukotriene B 4 that mediates chemotaxis. Nature 387, 620-624 7. Fiore, Romano, Reardon, E. and Serhan, C. N. (1993) Induction of functional lipoxin A 4 receptors in HL-60 cells. Blood 81, 3395-3403 8. Isakson, Seibert, Masferrer, Salvemini, Lee, and Needleman, P.
(1995) Discovery of a better aspirin. Advances in Prostaglandin, Thromboxane Leukotriene Research 23, 49-54 9. Chiang, Takano, Clish, C. Petasis, N. Tai, and Serhan, C. N.
(1998) Aspirin-triggered 15-epi-lipoxin A 4 (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific
LXA
4 ELISA. J. Pharmacol Exper. Ther. 287, 779-790 Serhan, C. Maddox, J. Petasis, N. Akritopoulou-Zanze, Papayianni, Brady, H. Colgan, S. and Madara, J. L. (1995) Design of lipoxin A 4 stable analogs that block transmigration and adhesion of human neutrophils.
Biochemistry 34, 14609-14615 11. Takano, Fiore, Maddox, J. Brady, H. Petasis, N. and Serhan, C.
N. (1997) Aspirin-triggered 15-epi-lipoxin A 4
(LXA
4 and LXA 4 Stable analogues are potent inhibitors of acute inflammation: Evidence for anti-inflammatory receptors. J. Exp. Med. 185, 1693-1704 12. Owman, Garzino-Demo, Cocchi, Popovic, Sabirsh, and Gallo, R. (1998) The leukotriene B 4 receptor functions as a novel type of coreceptor mediating entry of primary HIV-1 isolates into CD4-positive cells. Proc. Natl.
Acad Sci. 95, 9530-9534 13. Marcus, A. J. (1995) Aspirin as prophylaxis against colorectal cancer. N. Engl. J.
Med. 333, 656-658 14. Vainio, and Morgan, G. (1997) Aspirin for the second hundred years: new uses for an old drug. Pharmacol Toxicol 81, 151-152 Herschman, H. R. (1998) Recent progress in the cellular and molecular biology of prostaglandin synthesis. Trends in Cardiovasc. Med. 8, 145-150 16. Takano, Clish, C. Gronert, Petasis, and Serhan, C. N. (1998) Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A 4 and novel lipoxin B 4 stable analogues. J. Clin. Invest. 101, 819-826 17. Billah, M. Eckel, Mullmann, T. Egan, R. and Siegel, M. I. (1989) Phosphatidylcholine hydrolysis by phospholipase D determines phosphatidate and diglyceride levels in chemotactic peptide-stimulated human neutrophils.
Involvement of phsophatidate phosphohydrolase in signal transduction. J. Biol.
Chem. 264, 17069-17077 18. Wakelam, M. J. Martin, Hodgkin, M. Brown, Pettit, T. Cross, M. De Takats, P. and Reynolds, J. L. (1997) Role and regulation of phospholipase D activity in normal and cancer cells. Advances in Enzyme Regulation 37, 29-34 19. Olson, S. and Lambeth, J. D. (1996) Biochemistry and cell biology of phospholipase D in human neutrophils. Chem. Phys. Lipids 80, 3-19 Steed, P. Clark, K. Boyar, W. and Lasala, D. J. (1998) Characterization of human PLD2 and the analysis of PLD isoform splice variants. FASEB J. 12, 1309-1317 21. Martin, Saqib, K. Hodgkin, M. Brown, F. Pettit, T. Armstrong, and Wakelam, M. J. 0. (1997) Role and regulation of phospholipase D signalling. Biochem. Soc. Trans. 25, 1157-1160 22. Levy, B. Petasis, N. and Serhan, C. N. (1997) Polyisoprenyl phosphates in intracellular signalling. Nature 389, 985-989 23. Agwu, D. McPhail, L. Sozzani, Bass, D. and McCall, C. E. (1991) Phosphatidic acid as a second messenger in human polymorphonuclear leukocytes. Effects on activation ofNADPH oxidase. J. Clin. Invest. 88, 531-539 24. Pettit, T. Martin, Horton, Liossis, Lord, J. and Wakelam, M. J.
0. (1997) Diacylglycerol and phosphatidate generated by phospholipases C and D, respectively, have distinct fatty acid compositions and functions. J. Biol. Chem.
272, 17354-17359 Gomez-Cambronero, J. (1995) Immunoprecipitation of a phospholipase D activity with antiphosphotyrosine antibodies. J. Interferon Cytokine Res. 15, 877-885 26. Abousalham, Riviere, Teissere, and Verger, R. (1993) Improved purification and biochemical characterization of phospholipase D from cabbage.
Biochim. Biophys. Acta 1158, 1-7 27. Zhou, Chabot-Fletcher, Foley, J. Sarau, H. Tzimas, M. N., Winkler, J. and Torphy, T. J. (1993) Association between leukotriene B 4 induced phospholipase D activation and degranulation of human neutrophils.
Biochem. Pharmacol. 46, 139-148 28. Shechter, Fogelman, A. and Popjak, G. (1980) A deficiency of mixed function oxidase activities in the cholesterol biosynthetic pathway of human granulocytes. J. Lipid Res. 21, 277-283 29. Rabinowitz, J. Baker, D. Villanueva, T. Asanza, A. and Capuzzi, D.
M. (1992) Liver lipid profiles of adults taking therapeutic doses of aspirin. Lipids 27,311-314 Claria, and Serhan, C. N. (1995) Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc.
Natl. Acad. Sci. 92, 9475-9479 31. Serhan, C. N. (1997) Lipoxins and Novel Aspirin-Triggered 15-epi-Lipoxins: A Jungle of Cell-Cell Interactions or a Therapeutic Opportunity? Prostaglandins 53, 107-137 32. Exton, J. H. (1997) New developments in phospholipase D. J. Biol. Chem. 272, 15579-15582 33. Fensome, Whatmore, Morgan, Jones, and Cockcroft, S. (1998) ADP-ribosylation factor and Rho proteins mediate fMLP-dependent activation of phospholipase D in human neutrophils. J. Biol. Chem. 273, 13157-13164 34. Jarstfer, M. Blagg, B. S. Rogers, D. and Poulter, C. D. (1996) Biosynthesis of squalene. Evidence for a tertiary cyclopropylcarbinyl cationic intermediate in the rearrangement of presqualene diphosphate to squalene. J. Amer. Chem. Soc. 118, 13089-13090 Bach, T. J. (1995) Some new aspects of isoprenoid biosynthesis in plants -a review. Lipids 30, 191-202 One having ordinary skill in the art will appreciate further features and advantages of the invention based on the above-described embodiments.
Accordingly, the invention is not to be limited by what has been particularly shown and described, except as indicated by the appended claims. All publications and references cited herein, including those in the background section, are expressly incorporated herein by reference in their entirety.
Comprises/comprising and grammatical variations thereof when used in this specification are to be taken to specify the presence of stated features, integers, steps or components or groups thereof, but do not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.
Claims (8)
1. A method for treating phospholipase D (PLD) initiated polymorphoneutrophil (PMN) inflammation in a subject, comprising administering to the subject an effective anti-inflammatory amount of a lipoxin analog having the formula OH OH n wherein R 1 is a hydrogen atom, a pharmaceutically acceptable ester and pharmaceutically acceptable salts thereof, such that PLD initiated polymorphoneutrophil (PMN) inflammation is treated in a subject.
2. The method of claim 1, wherein said method is performed in vitro.
3. The method of claim 1, wherein said method is performed in vivo.
4. A method for treating phospholipase D (PLD) initiated superoxide generation or degranulation in a subject, comprising administering to the subject an effective anti-PLD amount of a lipoxin analog having the formula OH OH wherein R 1 is a hydrogen atom, a pharmaceutically acceptable ester and a pharmaceutically acceptable salts thereof, such that PLD initiated superoxide generation or granulation is treated in a subject. 38 00 O
5. The method of claim 4, wherein said method is performed in vitro. O
6. The method of claim 4, wherein said method is performed in vivo. 00
7. Use of the lipoxin analog described in claim 1 for the preparation of a medicament for the treatment of phospholipase D (PLD) initiated O 5 polymorphoneutrophil (PMN) inflammation in a subject.
8. Use of the lipoxin analog described in claim 4 for the preparation of a Vn medicament for the treatment of phospholipase D (PLD) initiated superoxide O generation or degranulation in a subject. BRIGHAM AND WOMEN'S HOSPITAL WATERMARK PATENT TRADE MARK ATTORNEYS P20170AU02
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005202416A AU2005202416B2 (en) | 1999-03-18 | 2005-06-03 | Regulation of phospholipase D activity |
AU2009208104A AU2009208104B2 (en) | 1999-03-18 | 2009-08-11 | Regulation of phospholipase D activity |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/125194 | 1999-03-18 | ||
PCT/US2000/006669 WO2000054761A2 (en) | 1999-03-18 | 2000-03-14 | Regulation of phospholipase d activity |
AU37451/00A AU780114B2 (en) | 1999-03-18 | 2000-03-14 | Regulation of phospholipase D activity |
AU2005202416A AU2005202416B2 (en) | 1999-03-18 | 2005-06-03 | Regulation of phospholipase D activity |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU37451/00A Division AU780114B2 (en) | 1999-03-18 | 2000-03-14 | Regulation of phospholipase D activity |
AU37451/00A Addition AU780114B2 (en) | 1999-03-18 | 2000-03-14 | Regulation of phospholipase D activity |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2009208104A Division AU2009208104B2 (en) | 1999-03-18 | 2009-08-11 | Regulation of phospholipase D activity |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2005202416A1 AU2005202416A1 (en) | 2005-06-30 |
AU2005202416B2 true AU2005202416B2 (en) | 2009-01-08 |
Family
ID=34705529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2005202416A Ceased AU2005202416B2 (en) | 1999-03-18 | 2005-06-03 | Regulation of phospholipase D activity |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2005202416B2 (en) |
-
2005
- 2005-06-03 AU AU2005202416A patent/AU2005202416B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2005202416A1 (en) | 2005-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU780114B2 (en) | Regulation of phospholipase D activity | |
Levy et al. | Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: A ‘stop’signaling switch for aspirin‐triggered lipoxin A4 | |
AU2009201390C1 (en) | A novel approach to antimicrobial host defense against gram-negative infections | |
US6653493B2 (en) | Lipoxin compounds and their use in treating cell proliferative disorders | |
US20120149771A1 (en) | Method for treating airway hyper-responsiveness with lipoxin analogs | |
US5475029A (en) | Farnesyl compounds as cholesterol lowering agents | |
AU2005202416B2 (en) | Regulation of phospholipase D activity | |
AU2009208104B2 (en) | Regulation of phospholipase D activity | |
AU2012203490A1 (en) | Regulation of phospholipase D activity | |
CA2768688A1 (en) | Regulation of phospholipase d activity | |
Spokas et al. | Leukotrienes, lipoxins, and hydroxyeicosatetraenoic acids | |
Recchiuti et al. | Lipoxins, resolvins, and the resolution of inflammation | |
EP1941875B1 (en) | Use of lipoxin analogs to promote cell defense against gram-negative infections | |
JPWO2006090756A1 (en) | Novel preventive or therapeutic agent for dyslipidemia, obesity and diabetes and use thereof | |
EP1911448B1 (en) | Lipoxins and Aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases | |
AU2012203640A1 (en) | Lipoxins and Asprin-Triggered Lipoxins and their Stable Analogs in the Treatment of Asthma and Inflammatory Airway Diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE APPLICANT FROM BRIGHAM AND WOMEN S HOSPITAL TO THE BRIGHAM AND WOMEN S HOSPITAL, INC. |
|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |